ReviewOncoimmunology2016
Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumors.
Review in Oncoimmunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- Car T Cells in Solid Tumors: Overcoming Obstacles.International journal of molecular sciences · 2024Review
- Beyond immune checkpoint blockade: emerging immunological strategies.Nature reviews. Drug discovery · 2021Review
- Engineered Antigen-Specific T Cells Secreting Broadly Neutralizing Antibodies: Combining Innate and Adaptive Immune Response against HIV.Molecular therapy. Methods & clinical development · 2020Article
- Analysis and Augmentation of the Immunologic Bystander Effects of CAR T Cell Therapy in a Syngeneic Mouse Cancer Model.Molecular therapy oncolytics · 2020Article
- Generation and Validation of an Antibody to Canine CD19 for Diagnostic and Future Therapeutic Purposes.Veterinary pathology · 2020Article
- Engineering Circulating Tumor Cells as Novel Cancer Theranostics.Theranostics · 2020Article
- Repurposing endogenous immune pathways to tailor and control chimeric antigen receptor T cell functionality.Nature communications · 2019Article
- Immunological Approaches Towards Cancer and Inflammation: A Cross Talk.Frontiers in immunology · 2018Review
- T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy.Laboratory investigation; a journal of technical methods and pathology · 2017Review
- CAR T-cell therapy of solid tumors.Immunology and cell biology · 2017Review
- Balanced secretion of anti-CEA × anti-CD3 diabody chains using the 2A self-cleaving peptide maximizes diabody assembly and tumor-specific cytotoxicity.Gene therapy · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Adoptive cell transfer (ACT) is an emerging anticancer therapy that has shown promise in various malignancies. Redirecting antigen specificity by genetically engineering T cells to stably express receptors has become an effective variant of ACT. A novel extension of this approach is to utilize engineered T cells to produce and deliver anticancer therapeutics that enhance cytotoxic T cell function and simultaneously inhibit immunosuppressive processes. Here, we review the potential of using T cells as therapeutic-secreting vehicles for immunotherapies and present theoretical and established arguments in support of further development of this unique cell-based immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.